Biocircuits: Market Realities, Technology Commitments
Executive SummaryBiocircuits was failing along with its breakthrough diagnostics invention until it saw that its raison d’etre was a marketplace, not a technology. That understanding allowed it to see other ways to make its projects into commercial realities. Instead of risking its remaining money on perfecting its breakthrough but intractable technology, it has switched to working on a product based on traditional technology. But Biocircuits' delays have cost it a major market opportunity and forced it to confront, at product launch, a marketplace in the process of radical transformation.
You may also be interested in...
Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, talks in a wide-ranging interview about the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.
Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.